2017 Heart Failure Review Course & Update

October 12-15, 2017
Scottsdale Marriott at McDowell Mountains
Scottsdale, AZ

www.hfsa.org/hfreview
HFSA’s Educational Patient Tools and Resources

Better engage your patients with their treatment plan!

The free Heart Failure Storylines app is ranked #1 in facilitating behavior change based on a Columbia University study. Tell your patients about the app today!

Download our helpful app. Heart Failure Storylines

www.hfsa.org
HANDS ON WORKSHOP:
DEVICE THERAPY FOR HEART FAILURE PATIENTS (NON-CME)
Thursday, October 12th | 7:00 PM | Valencia Ballroom
Sponsored by Medtronic

Program Description:
As part of the 2017 HFSA Comprehensive Review & Update, Medtronic is sponsoring a non-CME workshop on device therapy and heart failure management. The workshop will be didactic and hands on and will include 4 stations with 20-minute sessions.

The stations will focus on the following topics:
Station 1 - CRT education: Clinical evidence & guidelines for device therapy, device diagnostics, HF management tools and new technology & algorithms
Station 2 - Device programmers, CardioSight & CareLink HF
Station 3 - HeartWare™ HVAD™ System Overview, including Waveforms
Station 4 - HVAD Hands-on Alarms and Troubleshooting

Please join us for this exciting educational opportunity!

Target Audience: Cardiologists, internists, nurses, clinical pharmacists and other health professionals with a special interest in heart failure
ABOUT HFSA

The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care.

Our Vision
To significantly reduce the burden of heart failure.

Our Mission
Provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy.

Our Priorities

Cultivate
HFSA will cultivate a community of people committed to the delivery of heart failure care by:
• Fostering a multidisciplinary community that engages all who treat heart failure patients
• Ensuring long-term financial and organizational sustainability through reaccreditation, revenue diversification, and philanthropic giving

Educate
HFSA will educate providers and patients by:
• Developing, disseminating, and enhancing adoption and adherence of guidelines and evidence based therapies
• Increasing innovative educational opportunities for greater impact

Innovate
HFSA will inspire innovation by:
• Expanding and refining research programs; engaging investigators, government, industry, and patients
• Helping to drive the research agenda

Advocate
HFSA will expand and diversify its advocacy agenda by:
• Driving awareness to combat the growing crisis of heart failure
• Serving as a resource for government, industry, providers, and patients for programs and policies that will better serve the patient

Membership Information
Membership to the society is open to all health care professionals with an interest in heart failure. For more information about HFSA or to become a member, visit www.hfsa.org.

ON-SITE STAFF

The following staff will be on-site to assist you:

Michele Blair
Chief Executive Officer
mblair@hfsa.org

Jaime Abreu
Executive Vice President, CME and Educational Programs
jabreu@hfsa.org

Cynthia Dy
Manager, Marketing & Communications
cdy@hfsa.org
Course Information

The 2017 Comprehensive Heart Failure Review Course builds upon HFSA’s successful 2015 Review and 2016 Board Review Courses by incorporating results of new research studies, increasing focus on practical management recommendations, addressing issues encountered in practice, adding case studies, and providing breakout sessions in areas of special interest.

COURSE LOCATION
Scottsdale Marriott at McDowell Mountains
All course activities will be held in the Scottsdale Marriott at McDowell Mountains.

EDUCATION & COURSE FORMAT
Evidence-based presentations including guideline-based practice recommendations. Breakout sessions and case study sessions focusing on practical management issues.

Didactic presentations, cases, panel discussions, round table discussions, and small-group breakout sessions are included in this course.

INTENDED AUDIENCE
Cardiologists, internists, nurses, clinical pharmacists and other health professionals with a special interest in heart failure.

STATEMENT OF NEED & PROGRAM OVERVIEW
Despite progress, there are still significant variations among inpatient and outpatient heart failure practices in the US in the areas of prevention, assessment, drug and device therapy, treatment of comorbidities, patient education, hospital discharge instructions, and many other key areas. In many cases, practice patterns fall short of guideline recommendations or standards established by clinical trials.

This comprehensive review and update focuses on the practical management of heart failure from prevention through advanced disease. In addition to guideline-based standards of practice, speakers will address new and emerging therapies. Breakout sessions will provide an opportunity to pursue areas of individual interest in greater depth.

ATTENDEE RESOURCES
Additional resources including presentation slides, reading resources, faculty bios and additional course information can be found at www.hfsa.org/AttendeeRC17

ONDEMAND
Audio synced with slides will be captured and available for purchase through the HFSA OnDemand Library. This OnDemand program will be available during the course at a discount for attendees.

DISCLAIMER
The 2017 HFSA Comprehensive Review and Update is a forum for the open exchange and discussion of research results and scientific advancements in the field of heart failure. HFSA makes no representation or warranty as to the truth, originality, or accuracy of the information presented nor are the views expressed by the individual speakers necessarily the views of HFSA. HFSA supports the ACCME policy on evidence-based content and encourages faculty to adhere to these standards when preparing a presentation.
LEARNING OBJECTIVES

At the conclusion of this educational activity, participants will be able to:

1. Describe the epidemiology of heart failure and implement strategies for the prevention of heart failure.
2. Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms.
3. Assess and track the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.
4. Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents and non-pharmacologic options, such as diet and exercise; and implantable devices.
5. Apply appropriate care strategies for patients with pulmonary hypertension, RV failure, heart failure with preserved ejection fraction, cardiorenal syndrome, peripartum and infiltrative myopathies.
6. Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression.
7. Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care.
8. Describe characteristics of optimal candidates for cardiac transplantation or mechanical circulatory support.
9. Apply strategies for atrial and ventricular arrhythmia management.

COMPETENCIES ADDRESSED

ABMS core competencies:
- Patient care
- Medical knowledge
- Interpersonal and communication skills
- Professionalism
- Systems-based

ABIM-specified competency areas in advanced heart failure and transplant cardiology:
- Epidemiology and risk factors
- Pathophysiology of heart failure
- Hemodynamics and hemodynamic monitoring
- Heart failure and normal ejection fraction
- Heart failure with renal dysfunction/cardiorenal syndrome
- Diagnostic tests and procedures
- Acute decompensation of chronic heart failure
- Heart failure comorbidities
- Cardiomyopathies
- Pharmacotherapy
- Implantable devices
- Heart transplant
- Mechanical circulatory
Continuing Education Credits

**PHYSICIANS**

The Heart Failure Society of America designates this live activity for a maximum of **19.50 AMA PRA Category 1 Credits™**. Physicians should claim only credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **19.50 MOC points** in the Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**NURSES**

This continuing nursing education activity was approved by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91)

This activity is approved for **19.50 contact hours**. Approval valid through 10/05/2019; ONA #21191

**PHARMACISTS**

The University of North Carolina Eshelman School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). This program provides up to **19.50 contact hours** of continuing pharmacy education credit. To receive CE credit, participants must complete the CE attendance form and the online evaluation of the program.

Friday, October 13, 2017
UAN: 0046-9999-17-298-L01-P
(7.67 contact hours)

Saturday, October 14, 2017
UAN: 0046-9999-17-299-L01-P
(8.0 contact hours)

Sunday, October 15, 2017
UAN: 0046-9999-17-300-L01-P
(3.83 contact hours)

Statements of credit can be viewed and printed in CPE Monitor in approximately 2 to 3 weeks.

**No partial credit will be available. You must attend full day of sessions to receive credit**

**EVALUATION**

Attendees will be emailed a link to an evaluation at the end of the course. Upon completion of the evaluation, a credit certificate will be emailed within 5 business days. A follow-up evaluation will be sent approximately six weeks after the course.
Faculty Listing

Sean P. Pinney, MD  
Co-Chair  
Director, Advanced Heart Failure and Transplantation Program,  
The Mount Sinai Hospital  
New York, NY

Marie Galvao, MSN, ANP-BC, CHFN  
Co-Chair  
Lead Heart Failure Nurse Practitioner  
Center for Advanced Cardiac Therapy  
Montefiore Medical Center  
Bronx, NY

Sheryl L. Chow, PharmD, FCCP, FAHA, FHFS, BCPS, AQ-Cardiology  
Co-Chair  
Associate Professor  
Vice Chair, Western University of Health Sciences IRB Pharmacy Practice and Administration  
Western University of Health Sciences  
Pomona, CA

Cynthia Chauhan, MSW  
Patient Representative  
Wichita, KS

Jennifer L. Cook, MD  
Associate Professor of Medicine  
Director, Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation at Banner, University Medical Center Tuscon  
Director, Advanced Heart Disease Fellowship Program at University of Arizona College of Medicine  
University of Arizona Sarver Heart Center  
Tucson, AZ

Maria Rosa Costanzo, MD, FACC, FAHA  
Medical Director, Advocate Medical Group-Midwest Heart Specialists  
Heart Failure and Pulmonary Arterial Hypertension Programs  
Medical Director, Edward Hospital Center for Advanced Heart Failure  
Naperville, IL

Akshay S. Desai, MD, MPH, FHFS  
Associate Professor of Medicine  
Harvard Medical School  
Director, Heart Failure Disease Management Program  
Advanced Heart Disease Section  
Cardiovascular Division, Brigham and Women's Hospital  
Boston, MA

James C. Fang, MD, FHFS  
Professor of Medicine  
Chief, Division of Cardiovascular Medicine  
Executive Director, Cardiovascular Service Line  
University of Utah  
Salt Lake City, UT

Gregg C. Fonarow, MD, FACC, FAHA, FHFS  
Director, Ahmanson-UCLA Cardiomyopathy Center  
Co-Director, UCLA Preventative Cardiology Program  
Co-Chief, UCLA Division of Cardiology  
The Eliot Corday Chair in Cardiovascular Medicine and Science  
UCLA David Geffen School of Medicine  
Los Angeles, CA

J. Thomas Heywood, MD  
Medical Director, Advanced Heart Failure and Mechanical Circulatory Support Program  
Director, Heart Failure Research and Recovery Program  
Co-Director, Pulmonary Hypertension Program  
Scripps Clinic  
San Diego, CA

Susan M. Joseph, MD  
Associate Professor of Medicine  
Texas A&M University  
Medical Director, Mechanical Circulatory Support  
Baylor University Medical Center  
Dallas, TX
Ann S. Laramee, MS, ANP-BC, ACNS-BC, CHFN, ACHPN, FHFSA
University of Vermont Medical Center
Burlington, VT

Dawn M. Lombardo, DO, MSc
Assistant Professor, Medicine
University of Irvine School of Medicine
Irvine, CA

Alan S. Maisel, MD
Professor of Medicine
Director, Coronary Care Unit and Heart Failure Program, Veterans Affairs San Diego Healthcare System
San Diego, CA

Siva K. Mulpuru, MD
Consultant, Division of Cardiovascular Diseases, Department of Internal Medicine
Assistant Professor of Medicine
Mayo Clinic
Phoenix, AZ

Tien M.H. Ng, PharmD, FHfSA, FCCP, BCPS
AQ Cardiology
Associate Professor of Clinical Pharmacy and Medicine
Director, PGY2 Residency in Cardiology
Vice-Chair, Titus Department of Clinical Pharmacy
University of Southern California
Los Angeles, CA

Linda Ordway, RN, MS, ACNP, CHFN
NP, Clinical Care Manager, Cardiomyopathy Center Cardiac Transplant and VAD Program
Tufts Medical Center
Boston, MA

Robert Page II, PharmD, MSPH, BCPS (AQ-cards), FHfSA, FAHA
Professor of Clinical Pharmacy
Clinical Specialist, Division of Cardiology Section of Advanced Heart Failure/Heart Transplant
University of Colorado, Skaggs School of Pharmacy
Denver, CO

J. Herbert Patterson, PharmD, FCCP, FHfSA
Professor of Pharmacy and Research Professor of Medicine
Executive Vice Chair, Division of Pharmacotherapy and Experimental Therapeutics
UNC Eshelman School of Pharmacy
Chapel Hill, NC

Lisa D. Rathman, MSN, CRNP, CCRN
Lead Nurse Practitioner
Lancaster General Health CHF Clinic
Lancaster, PA

Jonathan D. Rich, MD FACC, FHfSA
Associate Professor of Medicine
Northwestern University, Feinberg School of Medicine
Medical Director, Mechanical Circulatory Support Program
Program Director, Advanced Heart Failure and Transplant Fellowship
Bluhm Cardiovascular Institute, Northwestern Memorial Hospital
Chicago, IL

Komandoor Srivathsan, MD
Director, Cardiac Electrophysiology Laboratory, Department of Cardiovascular Diseases
Consultant, Department of Cardiovascular Diseases
Associate Professor of Medicine
Mayo Clinic
Phoenix, AZ

D. Eric Steidley, MD
Medical Director, Heart Failure and Cardiac Transplantation
Assistant Professor of Medicine, Mayo Clinic School of Medicine
Mayo Clinic Arizona
Phoenix, AZ

Nancy K. Sweitzer, MD, PhD
Professor of Medicine, University of Arizona College of Medicine
Director, Sarver Heart Center
Chief, Division of Cardiology
Tucson, AZ
Jeffrey M. Testani, MD, MTR
Assistant Professor of Medicine (Cardiology)
Yale School of Medicine
Boston, MA

Orly Vardeny, PharmD, MS, FHFSA
Associate Professor of Medicine
University of Minnesota Medical School
Minneapolis, MN

Linda Wick, MSN, CNP, CHFN
University of MN Medical School
Sr. Director of Ambulatory Nursing
Sr. Operations Director Cardiology/Cardiovascular Surgery
M Health
Minneapolis, MN
<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean P. Pinney, MD</td>
<td>(Planning Committee &amp; Presenter) Consultant/Advisory Board: Abbott, CareDx Speaker/Honoraria: CareDx</td>
</tr>
<tr>
<td>Marie Galvao, MSN, ANP-BC, CHFN</td>
<td>(Planning Committee &amp; Presenter) Speaker/Honoraria: Merck Consultant/Advisory Board: Boston Scientific</td>
</tr>
<tr>
<td>Sheryl L. Chow, PharmD, FCCP, FAHA, FHFSA, BCPS, AQ-Cardiology</td>
<td>(Planning Committee &amp; Presenter) Speaker/Honoraria: Novartis Consultant/Advisory Board: Novartis</td>
</tr>
<tr>
<td>Cynthia Chauhan, MSW</td>
<td>(Patient Representative) Nothing to disclose</td>
</tr>
<tr>
<td>Jennifer L. Cook, MD</td>
<td>Research Grant: Abbott, Acetilon, Amgen</td>
</tr>
<tr>
<td>Maria Rosa Costanzo, MD, FACC, FAHA</td>
<td>Employment: Advocate Medical Group Research Grant: Abbott, Respicardia Consultant/Advisory Board: Abbott, Medtronic, Boston Scientific, Respicardia, CHF-Solutions, Axon Technologies, Re-Think Medical, Paragate</td>
</tr>
<tr>
<td>Akshay S. Desai, MD, MPH, FHFSA</td>
<td>Research Grant: Novartis Consultant/Advisory Board: Novartis, St. Jude/Abbott, AstraZeneca, Janssen, Relypsa, DalCor, Cheetah Medical</td>
</tr>
<tr>
<td>James C. Fang, MD, FHFSA</td>
<td>Consultant/Advisory Board: Actelion - SOPRANO Trial (DSMB), Caprico - ALLSTAR Trial (CEC), Amgen - Galactic HF Trial (Steering Committee), Novartis - EVALUATE HF Trial (Steering Committee), NIH – PVOMICS (OSMB), NIH – CTSN (Medical Monitor)</td>
</tr>
<tr>
<td>Gregg C. Fonarow, MD, FACC, FAHA, FHFSA</td>
<td>Speaker/Honoraria: Novartis Research Grant: NIH Consultant/Advisory Board: Novartis, Medtronic, Janssen, Amgen, ZS Pharma, St. Jude</td>
</tr>
<tr>
<td>J. Thomas Heywood, MD</td>
<td>Research Grant: Abbott, Medtronic Speaker/Honoraria: Abbott, Novartis Consultant/Advisory Board: Abbott, Medtronic, Novartis</td>
</tr>
<tr>
<td>Susan M. Joseph, MD</td>
<td>Speaker/Honoraria: Abbott Consultant/Advisory Board: Medtronic</td>
</tr>
<tr>
<td>Ann S. Laramee, MS, ANP-BC, ACNS-BC, CHFN, ACHPN, FHFSA</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Dawn M. Lombardo, DO, MSc</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Alan S. Maisel, MD</td>
<td>Consultant/Advisory Board: Critical Dx Research Grant: Novartis, Roche</td>
</tr>
<tr>
<td>Siva K. Mulpuru, MD</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Tien M.H. Ng, PharmD, FHFSA, FCCP, BCPS AQ Cardiology</td>
<td>Research Grant: Otsuka America Pharmaceuticals</td>
</tr>
<tr>
<td>Linda Ordway, RN, MS, ACNP, CHFN</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Robert Page II, PharmD, MSPH, BCPS (AQ-cards), FHFSA, FAHA</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>J. Herbert Patterson, PharmD, FCCP, FHFSA</td>
<td>Research Grant: Novartis, Amgen, Otsuka, Merck, Boehringer-Ingelheim Consultant/Advisory Board: Novartis</td>
</tr>
<tr>
<td>Lisa D. Rathman, MSN, CRNP</td>
<td>Consultant/Advisory Board: Medtronic, St. Jude, Stealth Biopharma Research Grant: St. Jude Speaker/Honoraria: St. Jude</td>
</tr>
</tbody>
</table>
Faculty & Planner Disclosures

Jonathan D. Rich, MD FACC, FHFA
Speaker/Honoraria: Novartis
Consultant/Advisory Board: Medtronic

Komandoor Srivathsan, MD
Nothing to disclose

D. Eric Steidley, MD
Research Grant: Heartware, Thoratec, Zoll

Nancy K. Sweitzer, MD, PhD
Research Grant: Merk, Novartis
Consultant/Advisory Board: Acordia, Cellular Logistics

Jeffrey M. Testani, MD, MTR
Research/Grant: FIRE1, Sanofi, Sequana Medical, Otsuka, Medtronic, Corvidia, Boehringer Ingelheim
Consultant/Advisory Board: FIRE1, Sanofi, Sequana Medical, Cardionomic

Orly Vardeny, PharmD, FHFA
Research Grant: Novartis
Consultant/Advisory Board: Novartis

Linda Wick, MSN, CNP, CHFN
Nothing to disclose

HFSA STAFF PLANNERS:

Jaime Abreu, MBA
HFSA EVP, CME & Educational Programs
(Planning Committee)
Nothing to disclose

Michele Blair
HFSA CEO
(Planning Committee)
Nothing to Disclose

Shauna Brown, MSI, PCMHC CCE
HFSA Director, Educational Programs
(Content Reviewer)
Nothing to disclose

As a provider accredited by ACCME, HFSA must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Directors, planning committee members, and speakers are required to disclose all relevant financial relationships. Faculty will also disclose off-label or investigational uses of pharmaceuticals or devices discussed in their presentations. Disclosures are published in course materials.
Agenda

Thursday, October 12, 2017

4:00 PM  Registration Open
5:00 PM  Opening Reception  Valencia Foyer
7:00 PM  Hands-on Workshop: Device Therapy for Heart Failure Patients (Non-CME)  Valencia Ballroom

Sponsored by Medtronic

Friday, October 13, 2017

7:00 AM  Continental Breakfast (Registration Open)
7:55 AM  Friday Introduction  Marie Galvao

SESSION 1 - Chronic HF  Valencia Ballroom
Moderator: Jonathan D. Rich

8:00 AM  Models and Mechanisms of HFrEF and HFpEF  James C. Fang
8:20 AM  New Guidelines Update  Gregg C. Fonarow
8:40 AM  ARNI’s and Ivabradine  Akshay S. Desai; Sheryl L. Chow
9:10 AM  Emerging Therapies for Chronic HF  Maria Rosa Costanzo
9:30 AM  HFpEF: Natural History and Contemporary Management  Dawn M. Lombardo
9:50 AM  Case Based Discussion  Case Presenter: Jonathan D. Rich
Panel: Sheryl L. Chow; Maria Rosa Costanzo; Akshay S. Desai; James C. Fang; Gregg C. Fonarow; Ann S. Laramee

10:10 AM  Refreshment Break

SESSION 2 - Acute HF  Valencia Ballroom
Moderator: Sheryl L. Chow

10:25 AM  Natural History & Patient Assessment  Gregg C. Fonarow
10:45 AM  Vasodilators & Inotropes: What’s New and What Works  Akshay S. Desai
11:05 AM  Acute HF: Congestion, Cardiorenal Syndrome and Diuretic Resistance  Jeffrey M. Testani
11:25 AM  Diuretics in Hospitalized Patients: Current Controversies and Emerging Therapies  Jeffrey M. Testani
11:45 AM  Case Based Discussion  Case Presenter: Sheryl L. Chow
Panel: Akshay S. Desai; Gregg C. Fonarow; Ann S. Laramee; Jeffrey M. Testani; Tien M.H. Ng
12:05 PM    Lunch

**SESSION 3 - Pulmonary Hypertension and RV Failure**  
*Moderator: Sean P. Pinney*  
*Valencia Ballroom*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 PM</td>
<td>Patient Assessment and Classification</td>
<td>Jonathan D. Rich</td>
</tr>
<tr>
<td>1:20 PM</td>
<td>Treating PAH in the Contemporary Era</td>
<td>Jonathan D. Rich</td>
</tr>
<tr>
<td>1:40 PM</td>
<td>Pulmonary Hypertension and Left HF</td>
<td>James C. Fang</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Right HF</td>
<td>Sean P. Pinney</td>
</tr>
<tr>
<td>2:20 PM</td>
<td>Case Based Discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Case Presenter: Sean P. Pinney</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panel: James C. Fang; Lisa D. Rathman; Jonathan D. Rich</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Refreshment Break</td>
<td></td>
</tr>
</tbody>
</table>

**BREAKOUT SESSIONS 1 (2:55 PM - 3:55 PM)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:55 PM</td>
<td>Assessment of Patient with New Onset HF</td>
<td>Marie Galvao; J. Herbert Patterson; Jonathan D. Rich</td>
</tr>
<tr>
<td>2:55 PM</td>
<td>Practical Application of Risk Prediction Models</td>
<td>Alan S. Maisel; Linda Ordway</td>
</tr>
<tr>
<td>2:55 PM</td>
<td>Sleep Disordered Breathing</td>
<td>James C. Fang; Robert Page; Lisa D. Rathman</td>
</tr>
</tbody>
</table>

**SESSION 4 - Patient Monitoring**  
*Moderator: Sean P. Pinney*  
*Valencia Ballroom*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 PM</td>
<td>Biomarker 2017 Update: What's Hot, What's Not?</td>
<td>Alan S. Maisel</td>
</tr>
<tr>
<td>4:20 PM</td>
<td>Invasive and Non-Invasive Hemodynamic Devices</td>
<td>J. Thomas Heywood</td>
</tr>
<tr>
<td>4:40 PM</td>
<td>Remote Monitoring: Smart Phones to Telehealth</td>
<td>Lisa D. Rathman</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>All session faculty</td>
<td></td>
</tr>
<tr>
<td>5:10 PM</td>
<td>Day Adjourns</td>
<td></td>
</tr>
</tbody>
</table>
# Agenda

**Saturday, October 14, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 AM</td>
<td>Continental Breakfast</td>
<td></td>
</tr>
<tr>
<td>7:55 AM</td>
<td>Saturday Introduction</td>
<td>Valencia Ballroom</td>
</tr>
<tr>
<td></td>
<td>Sean P. Pinney</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 5 - Cardiogenic Shock

**Moderator: Sheryl L. Chow**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>Clinical Variability within INTERMACS Profile I</td>
<td>Jennifer L. Cook</td>
</tr>
<tr>
<td>8:20 AM</td>
<td>Hemodynamics of Cardiogenic Shock and Devices</td>
<td>Sean P. Pinney</td>
</tr>
<tr>
<td>8:40 AM</td>
<td>Percutaneous Devices and ECMO</td>
<td>Susan M. Joseph</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Q&amp;A</td>
<td>All session faculty</td>
</tr>
</tbody>
</table>

### BREAKOUT SESSIONS 2 (9:15 AM - 10:15 AM)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15 AM</td>
<td>Tricks of the Trade: Challenges of RAAS Inhibition</td>
<td>Marie Galvao; Maria Rosa Costanzo; J. Herbert Patterson</td>
<td>Valencia Ballroom</td>
</tr>
<tr>
<td>9:15 AM</td>
<td>Advanced Hemodynamic Modeling</td>
<td>Sean P. Pinney; Susan M. Joseph</td>
<td>Barcelona I-II</td>
</tr>
<tr>
<td>9:15 AM</td>
<td>Troubleshooting LVAD Alarms</td>
<td>Jennifer L. Cook; Linda Ordway</td>
<td>Granada I-II</td>
</tr>
</tbody>
</table>

10:15 AM Refreshment Break

### SESSION 6 - MCS/Transplant

**Moderator: Sean P. Pinney**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 AM</td>
<td>Defining Advanced HF</td>
<td>Sean P. Pinney</td>
<td>Valencia Ballroom</td>
</tr>
<tr>
<td>10:50 AM</td>
<td>Heart Transplant Patient Selection</td>
<td>D. Eric Steidley</td>
<td></td>
</tr>
<tr>
<td>11:10 AM</td>
<td>Heart Transplant - Clinical Outcomes and Management</td>
<td>Jennifer L. Cook</td>
<td></td>
</tr>
<tr>
<td>11:30 AM</td>
<td>LVAD Patient Selection and Clinical Outcomes</td>
<td>Susan M. Joseph</td>
<td></td>
</tr>
<tr>
<td>11:50 AM</td>
<td>LVAD Adverse Events and Patient Management</td>
<td>Linda Ordway</td>
<td></td>
</tr>
<tr>
<td>12:10 PM</td>
<td>Managing Drug Interactions</td>
<td>Robert Page</td>
<td></td>
</tr>
<tr>
<td>12:30 PM</td>
<td>Q&amp;A</td>
<td>All session faculty</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Speaker(s)</td>
<td>Location</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>12:40 PM</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td>Cardiac Resynchronization Therapy - Recent Advances</td>
<td>Siva K. Mulpuru</td>
<td>Valencia Ballroom</td>
</tr>
<tr>
<td>1:53 PM</td>
<td>Arrhythmia Management: Antiarrhythmic Drugs and VT Ablation</td>
<td>Komandoor Srivathsan</td>
<td></td>
</tr>
<tr>
<td>2:16 PM</td>
<td>Impact of AFIB on HF</td>
<td>Komandoor Srivathsan</td>
<td></td>
</tr>
<tr>
<td>2:39 PM</td>
<td>Systemic Anticoagulation from VKA to NOAC</td>
<td>Tien M.H. Ng</td>
<td></td>
</tr>
<tr>
<td>3:02 PM</td>
<td>Prevention of Sudden Cardiac Death, Wearables and Implantables</td>
<td>J. Thomas Heywood</td>
<td></td>
</tr>
<tr>
<td>3:25 PM</td>
<td>Q&amp;A</td>
<td>All session faculty</td>
<td></td>
</tr>
<tr>
<td>3:40 PM</td>
<td>Refreshment Break</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**BREAKOUT SESSIONS 3 (3:55 PM - 4:40 PM)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:55 PM</td>
<td>How to Setup a HF Clinic and Diastolic HF Program</td>
<td>Dawn M. Lombardo; J. Herbert Patterson; Orly Vardeny; Linda Wick</td>
<td>Valencia Ballroom</td>
</tr>
<tr>
<td>3:55 PM</td>
<td>How to Setup a Remote Monitoring Program</td>
<td>J. Thomas Heywood; Robert Page; Lisa D. Rathman</td>
<td>Granada I-II</td>
</tr>
</tbody>
</table>

**BREAKOUT SESSIONS 4 (4:45 PM - 5:30 PM)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:45 PM</td>
<td>Having the Discussion - How to Make the Conversation Easier</td>
<td>Maria Rosa Costanzo; Ann S. Laramee; J. Herbert Patterson</td>
<td>Valencia Ballroom</td>
</tr>
<tr>
<td>4:45 PM</td>
<td>Practical Use of Biomarkers in the Clinical Setting</td>
<td>Sheryl L. Chow; Alan S. Maisel; Lisa D. Rathman</td>
<td>Barcelona I-II</td>
</tr>
<tr>
<td>4:45 PM</td>
<td>Transplant / VAD Case Review</td>
<td>Linda Ordway; Robert Page; Sean P. Pinney</td>
<td>Granada I-II</td>
</tr>
<tr>
<td>5:30 PM</td>
<td>Day Adjourns</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Agenda

### Sunday, October 15, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>Continental Breakfast</td>
<td></td>
</tr>
<tr>
<td>7:25 AM</td>
<td>Sunday Introduction</td>
<td>Valencia Ballroom</td>
</tr>
<tr>
<td></td>
<td><em>Sheryl L. Chow</em></td>
<td></td>
</tr>
<tr>
<td>7:30 AM</td>
<td><strong>SESSION 8 - Transitional Care / Palliative Care</strong></td>
<td>Valencia Ballroom</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator: Marie Galvao</strong></td>
<td></td>
</tr>
<tr>
<td>7:30 AM</td>
<td>Reducing 30-Day Readmissions</td>
<td>Orly Vardeny</td>
</tr>
<tr>
<td>7:50 AM</td>
<td>Transitioning Patients Out of the Hospital</td>
<td>Linda Wick</td>
</tr>
<tr>
<td>8:10 AM</td>
<td>Strategies for Keeping Patients Out of the Hospital</td>
<td>Linda Wick</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>&quot;They Are Not Ready for Palliative Care&quot; Really? Then When?</td>
<td>Ann S. Laramee</td>
</tr>
<tr>
<td>8:50 AM</td>
<td>Case Based Discussion</td>
<td>Marie Galvao; Ann S. Laramee; Orly Vardeny; Linda Wick</td>
</tr>
<tr>
<td>9:10 AM</td>
<td>Refreshment Break</td>
<td></td>
</tr>
<tr>
<td>9:25 AM</td>
<td><strong>SESSION 9 - Special Populations: Amyloid, HCM, Pregnancy and Diabetes</strong></td>
<td>Valencia Ballroom</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator: Sean P. Pinney</strong></td>
<td></td>
</tr>
<tr>
<td>9:25 AM</td>
<td>Hypertrophic Cardiomyopathies and Screening for Sudden Cardiac Death</td>
<td>J. Thomas Heywood</td>
</tr>
<tr>
<td>9:45 AM</td>
<td>Cardiac Amyloidosis</td>
<td>D. Eric Steidley</td>
</tr>
<tr>
<td>10:05 AM</td>
<td>Pregnancy and Peripartum Cardiomyopathy</td>
<td>D. Eric Steidley</td>
</tr>
<tr>
<td>10:25 AM</td>
<td>Inflammatory Cardiomyopathies &amp; Myocarditis</td>
<td>D. Eric Steidley</td>
</tr>
<tr>
<td>10:45 AM</td>
<td>Metabolic Challenges: Obesity, Diabetes, Anemia</td>
<td>Nancy K. Sweitzer</td>
</tr>
<tr>
<td>11:05 AM</td>
<td>Fireside Chat with Patient</td>
<td>Cynthia Chauhan; Nancy K. Sweitzer</td>
</tr>
<tr>
<td>11:25 AM</td>
<td>Q&amp;A</td>
<td>All session faculty</td>
</tr>
<tr>
<td>11:35 AM</td>
<td>Program Wrap-Up</td>
<td>Sean P. Pinney</td>
</tr>
<tr>
<td>11:40 AM</td>
<td>Program Adjourns</td>
<td>Valencia Ballroom</td>
</tr>
</tbody>
</table>
SCOTTSDALE MARRIOTT AT MCDOWELL MOUNTAINS
16770 North Perimeter Drive
Scottsdale, AZ 85260

Hotel Floor Plans
Change the Future of Heart Failure.
Be a member of the Heart Failure Society of America.
Now accepting 2018 Membership Applications! For more information, visit hfsa.org/join.

Our Vision
To significantly reduce the burden of heart failure.

Our Mission
Provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy.

Our Priorities

Cultivate
HFSA will cultivate a community of people committed to the delivery of heart failure care by:
- Fostering a multidisciplinary community that engages all who treat heart failure patients
- Ensuring long-term financial and organizational sustainability through reaccreditation, revenue diversification, and philanthropic giving

Educate
HFSA will educate providers and patients by:
- Developing, disseminating, and enhancing adoption and adherence of guidelines and evidence-based therapies
- Increasing innovative educational opportunities for greater impact

Innovate
HFSA will inspire innovation by:
- Expanding and refining research programs: engaging investigators, government, industry, and patients
- Helping to drive the research agenda

Advocate
HFSA will expand and diversify its advocacy agenda by:
- Driving awareness to combat the growing crisis of heart failure
- Serving as a resource for government, industry, providers, and patients for programs and policies that will better serve the patient
22nd Annual Scientific Meeting

September 15-18, 2018
Nashville, TN
Gaylord Opryland Hotel & Convention Center

Nashville

meeting.hfsa.org